API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2009
(Rs. In Lacs except per share data)
Particulars Quarter ended Quarter ended Nine Months Ended Nine Months Ended Year ended
31st Dec 2009 31st Dec 2008 31st Dec 2009 31st Dec 2008 31st Mar 2009
1.
(a)
(Net) Sales / Income from operations
11,703 9,161 34,657 27,465 37,650
(b) Other Operating Income
2. Expenditure
(a)
(Increase) / Decrease in stock in trade
81 670 (23) (517) 695
(b) Consumption of raw materials. 5,811 5,286 17,454 16,921 21,077
(c) Purchase of Traded Goods 2,190 612 5,944 2,132 3,443
(d) Employees cost 345 255 1,012 778 1,114
(e) Depreciation 341 266 1,004 785 1,104
(f) Other expenditure 1,796 1,336 4,956 4,113 5,648
(g) Total Expenditure 10,564 8,425 30,347 24,212 33,081
3.
Profit from Operating before Other Income
1,139 736 4,310 3,253 4,570
4. Other Income 3 10 34 16 17
5.
Profit before Interest & Exceptional Items
1,142 746 4,344 3,269 4,587
6. Interest 311 600 1,143 1,764 2,272
7.
Profit after Interest but before Exceptional Items
831 146 3,201 1,505 2,315
8. Exceptional Items - - - - -
9.
Profit from Ordinary Activities before Tax
831 146 3,201 1,505 2,315
10. Tax Expenses (Includes) 352 91 1,314 457 810
(a) Provision for Taxation 284 35 1,110 268 540
(b) Provision for FBT - 4 1 11 15
(c) Provision for Deffered Taxation 68 52 203 178 255
11.
Net profit from ordinary Activities after Tax
480 55 1,887 1,048 1,505
12.
Extraordinay Item (net of tax expenses )
- - - - -
13. Net Profit for the period 480 55 1,887 1,048 1,505
14.
Paid-up Equity Share Capital of Rs.10/- each.
1,211 1,171 1,211 1,171 1,171
15.
Reserves & Surplus (excluding revaluation reserves)
- - - - -
16. Basic & Diluted E P S(in Rs.) 3.96 0.47 15.59 8.95 12.85
17. Public shareholding
-Number of Shares 6051226 5627201 6051226 5627201 5495949
-Percentage of Total Shareholding 49.97 48.06 49.97 48.06 46.94
18. Promoters & Promoter Group
Shareholding
(a) Pledged/Encumbered
-Number of Shares NIL N.A NIL N.A NIL
-Percentage of shares( as a percentage of the total shareholding of promoter and promoter group) NIL N.A NIL N.A NIL
-Percentage of shares( as a percentage of total sharecapital of the Company) NIL N.A NIL N.A NIL
(b) Non-encumbered
-Number of Shares 6057324 N.A 6057324 N.A 6212601
-Percentage of shares( as a percentage of the total shareholding of promoter and promoter group) 100 N.A 100 N.A 100
-Percentage of shares( as a percentage of total sharecapital of the Company) 50.03 N.A 50.03 N.A 53.06

Notes :

1. The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 25th January, 2010

2. Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement as per AS - 17 'Segment Reporting' is not attracted.

3. The figures of the previous periods have been regrouped and rearranged wherever necessary.

4. Number of Investors complaints (i) pending at the beginning of quarter 1 (ii) received during the quarter : 10 (Iii) redressed : 10 (iv) pending at the end of the quarter : 1.

For and on behalf of the Board

FOR AARTI DRUGS LIMITED

Sd/-

Place : Mumbai Harshit M Savla

Date : 30th Oct, 2009 (Jt. Managing Director)

 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech